Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Anthropic's Scott White explains how AI agents evolved from chatbots to autonomous workers at VentureBeat Transform 2025, cutting enterprise tasks from weeks to minutes.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...